Emerging concepts of type I interferons in SLE pathogenesis and therapy

Area of Science:

• Immunology
• Rheumatology

Background:

• Type I interferons have long been implicated in systemic lupus erythematosus (SLE) pathogenesis.
• Previous understanding of type I interferon regulation and pathological roles in SLE is being revised.

Purpose of the Study:

• To present a new model of SLE pathogenesis based on updated understanding of type I interferons.
• To highlight the role of type I interferons in early and preclinical SLE phases.
• To discuss the clinical implications of type I interferons in SLE treatment.

Main Methods:

• Review of recent evidence on type I interferon regulation, genetic and epigenetic factors in SLE.
• Analysis of non-hematopoietic cellular sources of type I interferons.
• Examination of local type I interferon responses in various tissues during SLE progression.

Main Results:

• Type I interferons are regulated differently than previously assumed.
• Non-hematopoietic cells (e.g., keratinocytes, renal tubular cells) are significant sources of type I interferons.
• Local type I interferon activity is present in early, preclinical, and established SLE, even in normal-appearing tissues.

Conclusions:

• A revised model of SLE pathogenesis emphasizes the critical role of type I interferons.
• Interferon-blocking therapies are a valuable treatment strategy for SLE.
• Future SLE research should focus on disease reclassification and early/preclinical intervention strategies targeting the interferon system.